Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 8/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12577723 | 0.90 | PDCD1 (0.40) | FFAR4DRD1PDCD1CD274PTPN11 | |
| SCHEMBL2022751 | 0.80 | CD274 (0.40) | FFAR4PDCD1CD274FFAR1PDK2 | |
| SCHEMBL9934610 | 0.78 | FFAR1 (0.43) | PDCD1CD274FFAR1MAPT | |
| SCHEMBL12578187 | 0.77 | PARP10 (0.41) | PDCD1CD274FFAR1 | |
| SCHEMBL2909981 | 0.76 | DRD1 (0.40) | DRD1PDCD1CD274KDM4ECYP1A2 | |
| SCHEMBL13117432 | 0.75 | MAPT (0.41) | PDCD1CD274KDM4ECYP1A2MAPT | |
| SCHEMBL12640975 | 0.73 | CA12 (0.49) | FFAR4PDK2CYP3A4MAPT | |
| SCHEMBL12577725 | 0.73 | PDCD1 (0.36) | PDCD1CD274KDM4EMAPT | |
| SCHEMBL12578210 | 0.73 | FFAR1 (0.39) | FFAR4PDCD1CD274FFAR1MAPT | |
| SCHEMBL13139887 | 0.73 | CNR1 (0.41) | FFAR4FFAR1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-2011788-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2009-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186909-A1 | Oxadiazolidinedione Compound | GPR119, GPR39, GPR65 | FFAR4 54/4885DRD1 262/4885PDCD1 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.